Dec 11 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.RA PHARMACEUTICALS- PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 8,387,097 SHARES OF ITS COMMON STOCK, AT A PUBLIC OFFERING PRICE OF $15.50 PER SHARE.
Full Article
Dec 10 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2 TRIAL OF ZILUCOPLAN IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS.RA PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2 TRIAL OF ZILUCOPLAN IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS.RA PHARMACEUTICALS INC - CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT REDUCTIONS IN BOTH QMG AND MG-ADL.RA PHARMACEUTICALS INC - PRIMARY AND KEY SECONDARY ENDPOINTS IN STUDY MET IN A BROAD SPECTRUM OF PATIENTS WITH GMG.RA PHARMACEUTICALS - PLANS TO ENGAGE WITH FDA IN H1 2019 REGARDING DESIGN OF A PHASE 3 TRIAL FOR 0.3 MG/KG DOSE OF ZILUCOPLAN VERSUS PLACEBO IN GMG PATIENTS.
Full Article
Sept 26 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMA ANNOUNCES POSITIVE RESULTS FROM PHASE 1B PHARMACOKINETIC STUDY OF ZILUCOPLAN (RA101495 SC) IN PATIENTS WITH RENAL IMPAIRMENT.RA PHARMACEUTICALS INC - PLANS TO INITIATE A GLOBAL, PIVOTAL, SINGLE-ARM PHASE 3 TRIAL IN TREATMENT-NAÏVE PNH PATIENTS DURING FIRST HALF OF 2019.RA PHARMACEUTICALS-PK PROFILE OF ZILUCOPLAN WAS CONSISTENT ACROSS BOTH GROUPS, WITH EXPOSURES SIMILAR IN RENALLY-IMPAIRED PATIENTS, HEALTHY VOLUNTEERS.RA PHARMACEUTICALS INC - THERE WERE NO ADVERSE EVENTS REPORTED IN RESULTS.
Full Article
Aug 8 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND ANNOUNCES EARLY COMPLETION OF ENROLLMENT IN GMG PHASE 2 PROGRAM.Q2 LOSS PER SHARE $0.49.Q2 EARNINGS PER SHARE VIEW $-0.55 -- THOMSON REUTERS I/B/E/S.COMPANY EXPECTS THAT ITS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS THROUGH END OF 2019.AS OF JUNE 30, 2018, RA PHARMA REPORTED TOTAL CASH AND CASH EQUIVALENTS OF $95.1 MILLION.TOP-LINE DATA FOR PHASE 2 TRIAL OF RA101495 SC NOW EXPECTED AROUND YEAR-END 2018.
Full Article
Dec 21 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS INITIATES DOSING IN PHASE 2 CLINICAL TRIAL EVALUATING RA101495 SC IN GENERALIZED MYASTHENIA GRAVIS PATIENTS.RA PHARMACEUTICALS INC - TOPLINE DATA FROM SECOND CLINICAL INDICATION OF RA101495 SC EXPECTED FIRST HALF OF 2019.
Full Article
Nov 9 (Reuters) - Ra Pharmaceuticals Inc :Ra pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.68.Q3 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.As of September 30, 2017, Ra Pharma reported total cash and equivalents of $84.1 million.Company expects that its cash and cash equivalents will be sufficient to fund operations through end of 2018.
Full Article
Nov 1 (Reuters) - Ra Pharmaceuticals Inc :Ra Pharmaceuticals Inc files for mixed shelf offering of up to $250 million - SEC filing.
Full Article
Earnings vs. 
Estimates